Document is current
Any future updates will be listed below
-
Authors
Ibáñez-Cabellos, José Santiago
García-Giménez, José Luis
Escobar, Javier
Pallardó, Federico V.
Mena-Mollá, Salvador
-
Funding
Funding for this research was provided by:
thank “Promoció del Talent” funding from Agencia Valenciana de Innovació (INNTA2/2020/4)
The Instituto Valenciano de Competitividad Empresarial (IVACE) Generalitat Valenciana through CREATEC-CV program (IMCBTA/2018/29)
Universitat de Valencia
- License Information
-
More Information
Article History
Received: 30 January 2026
Accepted: 30 April 2026
First Online: 6 May 2026
Declarations
:
: Federico V. Pallardó, José Luis García-Giménez, and Salvador Mena-Mollá are founders and shareholders of EpiDisease S.L., a biotechnology spin-off created from the Consortium Centre for Biomedical Network Research on Rare Diseases (CIBERER, Instituto de Salud Carlos III), INCLIVA Biomedical Research Institute, and the University of Valencia. Javier Escobar is a founder and shareholder of OverGenes S.L. José Santiago Ibáñez-Cabellos was employed at EpiDisease during the period in which the analyses and manuscript preparation were conducted.
: During the preparation of this work, Salvador Mena-Mollá used ChatGPT to improve the readability of the manuscript. After using this tool, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.
